"Taxoids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
| Descriptor ID |
D043823
|
| MeSH Number(s) |
D02.455.426.392.368.242.888 D02.455.849.291.850
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Taxoids".
Below are MeSH descriptors whose meaning is more specific than "Taxoids".
This graph shows the total number of publications written about "Taxoids" by people in this website by year, and whether "Taxoids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 1 | 4 |
| 2006 | 0 | 3 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 3 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 3 | 0 | 3 |
| 2021 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Taxoids" by people in Profiles.
-
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026 Feb 05; 394(6):551-562.
-
IRE1a silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024 Dec 12; 187(25):7248-7266.e34.
-
The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo. Cancer Chemother Pharmacol. 2023 02; 91(2):191-201.
-
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).
-
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021 07; 32(7):896-905.
-
Factors influencing treatment of veterans with advanced prostate cancer. Cancer. 2021 07 01; 127(13):2311-2318.
-
Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends. Int J Nanomedicine. 2018; 13:3145-3161.
-
Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Res. 2018 04 16; 20(1):27.
-
Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
-
The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells. J Neurooncol. 2018 May; 137(3):481-492.